autologous p53-specific T cells

Autologous p53-specific T cells are a form of adoptive cell therapy involving the administration of a patient's own T lymphocytes that have been selected or genetically engineered to recognize and destroy cancer cells expressing the p53 protein, particularly its mutated forms. The p53 protein is a critical tumor suppressor that is frequently mutated in a wide variety of human cancers, often resulting in the presentation of specific 'hotspot' mutation-derived neoantigens on the cell surface via human leukocyte antigens (HLA). In this therapy, T cells are typically harvested from the patient and either expanded (if naturally occurring p53-reactive T cells are present) or genetically modified with a T-cell receptor (TCR) specific to a particular p53 mutation, such as R175H, R273H, or R248W, restricted to a specific HLA type (e.g., HLA-A*02:01). Upon re-infusion into the patient, usually following lymphodepleting chemotherapy, these cells target tumor cells with high precision. This approach is primarily investigated for advanced solid tumors, including ovarian, colorectal, and breast cancers, and is often administered alongside interleukin-2 (IL-2) to promote the expansion and persistence of the infused cells.

Other names

autologous T-cell therapy targeting p53mutant p53-specific T-cellsp53-targeted autologous T-lymphocytesp-53-targeted autologous T-lymphocytesp 53-targeted autologous T-lymphocytes